Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
暂无分享,去创建一个
J. Wagner | E. Pamer | B. Blazar | D. Krause | N. Berliner | J. Crouch | I. Pilip | J. G. Howe | D. Cooper | S. Seropian | Ingrid M. Pilip | D. Cooper | J. Wagner | N. A. Marshall | R. Formica | J. Howe | Natalie A. Marshall | Richard Formica | Diane Krause
[1] I. Ernberg,et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.
[2] R. Merion. Current use of polyclonal antilymphocyte antibody preparations. , 1999, Transplantation proceedings.
[3] D. Nixon,et al. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. , 1999, The Journal of infectious diseases.
[4] Eric G. Pamer,et al. H2-M3–Restricted T Cells in Bacterial Infection , 1999, The Journal of experimental medicine.
[5] C. Pitcher,et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.
[6] D. Busch,et al. T Cell Affinity Maturation by Selective Expansion during Infection , 1999, The Journal of experimental medicine.
[7] S. Rowland-Jones,et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. , 1999, Journal of immunology.
[8] M. Horowitz,et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. , 1998, Blood.
[9] D. Srivastava,et al. Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .
[10] V. Levitsky,et al. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. , 1998, Journal of immunology.
[11] Eric G. Pamer,et al. Evolution of a Complex T Cell Receptor Repertoire during Primary and Recall Bacterial Infection , 1998, The Journal of experimental medicine.
[12] A. Burroughs,et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. , 1998, Journal of immunology.
[13] J. Yewdell,et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. , 1998, Journal of immunology.
[14] Todd M. Allen,et al. Analysis of Gag-specific Cytotoxic T Lymphocytes in Simian Immunodeficiency Virus–infected Rhesus Monkeys by Cell Staining with a Tetrameric Major Histocompatibility Complex Class I–Peptide Complex , 1998, The Journal of experimental medicine.
[15] G. Ogg,et al. Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.
[16] A. McMichael,et al. A New Look at T Cells , 1998, The Journal of experimental medicine.
[17] D. Knowles. Immunodeficiency-associated lymphoproliferative disorders. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[18] M A Nowak,et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.
[19] D. Busch,et al. Coordinate regulation of complex T cell populations responding to bacterial infection. , 1998, Immunity.
[20] J. Altman,et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.
[21] V. Levitsky,et al. Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes. , 1997, Journal of immunology.
[22] R. Champlin,et al. Allogeneic blood stem cell transplantation , 1997 .
[23] K. Lucas,et al. Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts , 1997, Immunological reviews.
[24] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[25] S. Ildstad,et al. Bone marrow transplantation for therapy in autoimmune disease , 1997, Stem cells.
[26] E. Pamer,et al. Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. , 1997, Journal of immunology.
[27] P. Anderlini,et al. The Use of Mobilized Peripheral Blood Stem Cells from Normal Donors for Allografting , 1997, Stem Cells.
[28] J. Fay,et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. , 1996, Blood.
[29] Philip J. R. Goulder,et al. Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.
[30] Malcolm K. Brenner,et al. Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.
[31] G. Heller,et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. , 1996, Blood.
[32] V. Levitsky,et al. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4 , 1996, The Journal of experimental medicine.
[33] N. Ellison. Hematology, Basic Principles and Practice, 2nd ed , 1995 .
[34] R. Hoffman,et al. Hematology: Basic Principles and Practice , 1995 .
[35] R. Krance,et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.
[36] M. Ladanyi,et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.
[37] E Picozza,et al. A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation. , 1993, BioTechniques.
[38] G. Miller,et al. Detection of Epstein‐Barr virus in the brain by the polymerase chain reaction , 1992, Annals of neurology.
[39] S. Riddell,et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.
[40] H. Deeg,et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.
[41] H. Takada,et al. Epstein–Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond–Blackfan anemia , 2000, Bone Marrow Transplantation.
[42] N. Sirvent,et al. First report of Epstein-Barr virus lymphoproliferative disease after cord blood transplantation , 2000, Bone Marrow Transplantation.
[43] A. Marmont. Stem cell transplantation for severe autoimmune diseases: progress and problems. , 1998, Haematologica.
[44] D. Srivastava,et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.